Compare CZFS & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CZFS | SABS |
|---|---|---|
| Founded | 1984 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 288.7M | 263.8M |
| IPO Year | 1995 | 2020 |
| Metric | CZFS | SABS |
|---|---|---|
| Price | $83.00 | $3.80 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $10.75 |
| AVG Volume (30 Days) | 26.1K | ★ 481.3K |
| Earning Date | 04-29-2026 | 05-12-2026 |
| Dividend Yield | ★ 3.10% | N/A |
| EPS Growth | 30.26 | ★ 78.53 |
| EPS | ★ 4.28 | N/A |
| Revenue | ★ $9,881,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.64 | N/A |
| P/E Ratio | $19.23 | ★ N/A |
| Revenue Growth | ★ 2.82 | N/A |
| 52 Week Low | $52.35 | $1.85 |
| 52 Week High | $83.37 | $5.15 |
| Indicator | CZFS | SABS |
|---|---|---|
| Relative Strength Index (RSI) | 65.62 | 54.76 |
| Support Level | $55.53 | $3.68 |
| Resistance Level | $83.37 | $4.09 |
| Average True Range (ATR) | 3.12 | 0.17 |
| MACD | 0.32 | 0.03 |
| Stochastic Oscillator | 90.93 | 72.58 |
Citizens Financial Services Inc is a Pennsylvania-chartered bank and trust company. The company through its banking subsidiary provides banking activities and services for individual, business, governmental and institutional customers. Its activities and services principally include checking, savings, and time deposit accounts; residential, commercial and agricultural real estate, commercial and industrial, state and political subdivision and consumer loans; and a variety of other specialized financial services. The Trust and Investment division of the Bank offers a full range of client investment, estate, mineral management, and retirement services.
SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.